Additional Volume Molnupiravir (EIDD-2801/MK-4482) Supply Agreement for Pandemic Purposes
What the buyer wrote
Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative. <br/>This agreement is for the procurement of 1,750,000 units of Molnupiravir (EIDD-2801/MK-4482). It is one of the first oral and direct-acting antiviral drugs globally and the first to receive regulatory approval and is part of the UK’s multi-layered approach to COVID-19.
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- Additional Volume Molnupiravir (EIDD-2801/MK-4482) Supply Agreement for Pandemic Purposes
- How they are buying
- Given to one supplier, no competitionNobody else was asked, and the buyer has to be able to justify that.
- Type
- goods
- Kind of work
- Pharmacy and medicines
Who the buyer named
Stephen Boddy was the named contact on this notice.